Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women

We evaluated adherence with raloxifene therapy compared with daily bisphosphonate in Asian postmenopausal women at increased risk of osteoporotic fractures. In this 12-month observational study conducted in Asia (Hong Kong, Malaysia, Pakistan, Philippines, Singapore, Taiwan), 984 postmenopausal women (aged 55 years or older) were treated with raloxifene 60mg/day (n = 707; 72%) or daily bisphosphonate (alendronate 10mg/day; n = 206; 21%, or risedronate 5mg/day; n = 71; 7%) during their...